CN101721637A - 一种治疗妇女更年期综合症的中药复方制剂及其制备方法 - Google Patents
一种治疗妇女更年期综合症的中药复方制剂及其制备方法 Download PDFInfo
- Publication number
- CN101721637A CN101721637A CN200910242977A CN200910242977A CN101721637A CN 101721637 A CN101721637 A CN 101721637A CN 200910242977 A CN200910242977 A CN 200910242977A CN 200910242977 A CN200910242977 A CN 200910242977A CN 101721637 A CN101721637 A CN 101721637A
- Authority
- CN
- China
- Prior art keywords
- radix
- chinese medicinal
- compound chinese
- medicinal preparation
- climacteric syndrome
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003814 drug Substances 0.000 title claims abstract description 58
- 238000002360 preparation method Methods 0.000 title claims abstract description 28
- 150000001875 compounds Chemical class 0.000 title claims abstract description 17
- 206010027304 Menopausal symptoms Diseases 0.000 title abstract description 4
- 230000000694 effects Effects 0.000 claims abstract description 20
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 19
- 229940079593 drug Drugs 0.000 claims description 33
- 210000000582 semen Anatomy 0.000 claims description 27
- 208000011580 syndromic disease Diseases 0.000 claims description 21
- 238000011282 treatment Methods 0.000 claims description 19
- VYQNWZOUAUKGHI-UHFFFAOYSA-N monobenzone Chemical compound C1=CC(O)=CC=C1OCC1=CC=CC=C1 VYQNWZOUAUKGHI-UHFFFAOYSA-N 0.000 claims description 17
- 239000000706 filtrate Substances 0.000 claims description 12
- 241001619461 Poria <basidiomycete fungus> Species 0.000 claims description 11
- 239000000843 powder Substances 0.000 claims description 10
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 9
- 239000012567 medical material Substances 0.000 claims description 8
- 238000009835 boiling Methods 0.000 claims description 7
- 238000000605 extraction Methods 0.000 claims description 7
- 239000008187 granular material Substances 0.000 claims description 7
- 230000006837 decompression Effects 0.000 claims description 6
- 239000000284 extract Substances 0.000 claims description 5
- 238000000034 method Methods 0.000 claims description 5
- 239000002775 capsule Substances 0.000 claims description 4
- 239000012141 concentrate Substances 0.000 claims description 4
- 238000001035 drying Methods 0.000 claims description 4
- 238000009472 formulation Methods 0.000 claims description 4
- 239000000203 mixture Substances 0.000 claims description 4
- 238000010992 reflux Methods 0.000 claims description 4
- 238000001914 filtration Methods 0.000 claims description 3
- 235000011438 Albizia odoratissima Nutrition 0.000 claims description 2
- 241000208966 Polygala Species 0.000 claims description 2
- 238000002386 leaching Methods 0.000 claims description 2
- 239000007788 liquid Substances 0.000 claims description 2
- 239000006187 pill Substances 0.000 claims description 2
- 238000002791 soaking Methods 0.000 claims description 2
- 229940098465 tincture Drugs 0.000 claims description 2
- 239000000463 material Substances 0.000 claims 3
- 241000220433 Albizia Species 0.000 claims 1
- 239000007935 oral tablet Substances 0.000 claims 1
- 229940096978 oral tablet Drugs 0.000 claims 1
- 229940023488 pill Drugs 0.000 claims 1
- 210000000952 spleen Anatomy 0.000 abstract description 19
- 210000004185 liver Anatomy 0.000 abstract description 17
- 239000000546 pharmaceutical excipient Substances 0.000 abstract description 9
- 230000003750 conditioning effect Effects 0.000 abstract description 2
- 238000005728 strengthening Methods 0.000 abstract description 2
- 240000007185 Albizia julibrissin Species 0.000 abstract 1
- 241000213006 Angelica dahurica Species 0.000 abstract 1
- 244000236521 Bupleurum rotundifolium Species 0.000 abstract 1
- 235000015221 Bupleurum rotundifolium Nutrition 0.000 abstract 1
- 244000077995 Coix lacryma jobi Species 0.000 abstract 1
- 241000146384 Glaux Species 0.000 abstract 1
- 241000234435 Lilium Species 0.000 abstract 1
- 244000170916 Paeonia officinalis Species 0.000 abstract 1
- 235000006484 Paeonia officinalis Nutrition 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- 239000002994 raw material Substances 0.000 abstract 1
- 241000699670 Mus sp. Species 0.000 description 34
- 239000002245 particle Substances 0.000 description 19
- 210000002784 stomach Anatomy 0.000 description 18
- 210000002216 heart Anatomy 0.000 description 14
- 239000008280 blood Substances 0.000 description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 9
- 201000010099 disease Diseases 0.000 description 8
- 230000002567 autonomic effect Effects 0.000 description 7
- 210000004369 blood Anatomy 0.000 description 7
- 230000001914 calming effect Effects 0.000 description 7
- 235000009508 confectionery Nutrition 0.000 description 7
- 208000024891 symptom Diseases 0.000 description 7
- 229920002472 Starch Polymers 0.000 description 6
- 230000000968 intestinal effect Effects 0.000 description 6
- 210000001672 ovary Anatomy 0.000 description 6
- 239000008107 starch Substances 0.000 description 6
- 235000019698 starch Nutrition 0.000 description 6
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 5
- 230000003203 everyday effect Effects 0.000 description 5
- 230000002496 gastric effect Effects 0.000 description 5
- 239000000976 ink Substances 0.000 description 5
- 206010022437 insomnia Diseases 0.000 description 5
- 210000003734 kidney Anatomy 0.000 description 5
- 210000004072 lung Anatomy 0.000 description 5
- 230000002936 tranquilizing effect Effects 0.000 description 5
- 238000005303 weighing Methods 0.000 description 5
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 230000007812 deficiency Effects 0.000 description 4
- 239000002552 dosage form Substances 0.000 description 4
- 210000005036 nerve Anatomy 0.000 description 4
- 206010012735 Diarrhoea Diseases 0.000 description 3
- 206010022998 Irritability Diseases 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 208000008238 Muscle Spasticity Diseases 0.000 description 3
- QGMRQYFBGABWDR-UHFFFAOYSA-M Pentobarbital sodium Chemical compound [Na+].CCCC(C)C1(CC)C(=O)NC(=O)[N-]C1=O QGMRQYFBGABWDR-UHFFFAOYSA-M 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 206010061428 decreased appetite Diseases 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 229960002275 pentobarbital sodium Drugs 0.000 description 3
- 239000013641 positive control Substances 0.000 description 3
- 230000002980 postoperative effect Effects 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 208000018198 spasticity Diseases 0.000 description 3
- 230000009182 swimming Effects 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- AHOUBRCZNHFOSL-YOEHRIQHSA-N (+)-Casbol Chemical group C1=CC(F)=CC=C1[C@H]1[C@H](COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-YOEHRIQHSA-N 0.000 description 2
- DNXIKVLOVZVMQF-UHFFFAOYSA-N (3beta,16beta,17alpha,18beta,20alpha)-17-hydroxy-11-methoxy-18-[(3,4,5-trimethoxybenzoyl)oxy]-yohimban-16-carboxylic acid, methyl ester Natural products C1C2CN3CCC(C4=CC=C(OC)C=C4N4)=C4C3CC2C(C(=O)OC)C(O)C1OC(=O)C1=CC(OC)=C(OC)C(OC)=C1 DNXIKVLOVZVMQF-UHFFFAOYSA-N 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 241000721047 Danaus plexippus Species 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 206010033557 Palpitations Diseases 0.000 description 2
- AHOUBRCZNHFOSL-UHFFFAOYSA-N Paroxetine hydrochloride Natural products C1=CC(F)=CC=C1C1C(COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-UHFFFAOYSA-N 0.000 description 2
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 2
- LCQMZZCPPSWADO-UHFFFAOYSA-N Reserpilin Natural products COC(=O)C1COCC2CN3CCc4c([nH]c5cc(OC)c(OC)cc45)C3CC12 LCQMZZCPPSWADO-UHFFFAOYSA-N 0.000 description 2
- QEVHRUUCFGRFIF-SFWBKIHZSA-N Reserpine Natural products O=C(OC)[C@@H]1[C@H](OC)[C@H](OC(=O)c2cc(OC)c(OC)c(OC)c2)C[C@H]2[C@@H]1C[C@H]1N(C2)CCc2c3c([nH]c12)cc(OC)cc3 QEVHRUUCFGRFIF-SFWBKIHZSA-N 0.000 description 2
- 210000000683 abdominal cavity Anatomy 0.000 description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000004596 appetite loss Effects 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 239000003610 charcoal Substances 0.000 description 2
- 230000009429 distress Effects 0.000 description 2
- 230000002996 emotional effect Effects 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 210000000232 gallbladder Anatomy 0.000 description 2
- 230000037308 hair color Effects 0.000 description 2
- 241000411851 herbal medicine Species 0.000 description 2
- 229910052742 iron Inorganic materials 0.000 description 2
- 230000002262 irrigation Effects 0.000 description 2
- 238000003973 irrigation Methods 0.000 description 2
- 208000019017 loss of appetite Diseases 0.000 description 2
- 235000021266 loss of appetite Nutrition 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 206010025482 malaise Diseases 0.000 description 2
- 239000002398 materia medica Substances 0.000 description 2
- 230000003340 mental effect Effects 0.000 description 2
- 238000010172 mouse model Methods 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 230000002611 ovarian Effects 0.000 description 2
- 229960002296 paroxetine Drugs 0.000 description 2
- WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 210000001187 pylorus Anatomy 0.000 description 2
- BJOIZNZVOZKDIG-MDEJGZGSSA-N reserpine Chemical compound O([C@H]1[C@@H]([C@H]([C@H]2C[C@@H]3C4=C([C]5C=CC(OC)=CC5=N4)CCN3C[C@H]2C1)C(=O)OC)OC)C(=O)C1=CC(OC)=C(OC)C(OC)=C1 BJOIZNZVOZKDIG-MDEJGZGSSA-N 0.000 description 2
- 229960003147 reserpine Drugs 0.000 description 2
- MDMGHDFNKNZPAU-UHFFFAOYSA-N roserpine Natural products C1C2CN3CCC(C4=CC=C(OC)C=C4N4)=C4C3CC2C(OC(C)=O)C(OC)C1OC(=O)C1=CC(OC)=C(OC)C(OC)=C1 MDMGHDFNKNZPAU-UHFFFAOYSA-N 0.000 description 2
- 239000002002 slurry Substances 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 2
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 2
- 208000016303 spleen symptom Diseases 0.000 description 2
- 238000012109 statistical procedure Methods 0.000 description 2
- 238000005494 tarnishing Methods 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- CHZJRGNDJLJLAW-RIQJQHKOSA-N (8r,9s,13s,14s,16r,17r)-3-cyclopentyloxy-17-ethynyl-13-methyl-7,8,9,11,12,14,15,16-octahydro-6h-cyclopenta[a]phenanthrene-16,17-diol Chemical compound C([C@@H]1[C@@H](C2=CC=3)CC[C@]4([C@H]1C[C@@H](O)[C@@]4(O)C#C)C)CC2=CC=3OC1CCCC1 CHZJRGNDJLJLAW-RIQJQHKOSA-N 0.000 description 1
- 240000000559 Albizia odoratissima Species 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 206010012335 Dependence Diseases 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 206010013954 Dysphoria Diseases 0.000 description 1
- 235000009161 Espostoa lanata Nutrition 0.000 description 1
- 240000001624 Espostoa lanata Species 0.000 description 1
- 208000004356 Hysteria Diseases 0.000 description 1
- 238000012449 Kunming mouse Methods 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 208000019255 Menstrual disease Diseases 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 241000590428 Panacea Species 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 208000001431 Psychomotor Agitation Diseases 0.000 description 1
- 206010038743 Restlessness Diseases 0.000 description 1
- 208000032023 Signs and Symptoms Diseases 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000000923 adrenergic beta-3 receptor antagonist Substances 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 230000001430 anti-depressive effect Effects 0.000 description 1
- 230000001142 anti-diarrhea Effects 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 229940125713 antianxiety drug Drugs 0.000 description 1
- 239000000935 antidepressant agent Substances 0.000 description 1
- 229940005513 antidepressants Drugs 0.000 description 1
- 210000000436 anus Anatomy 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 230000001174 ascending effect Effects 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 1
- 210000003710 cerebral cortex Anatomy 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 208000012839 conversion disease Diseases 0.000 description 1
- 239000006184 cosolvent Substances 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 230000002354 daily effect Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 230000000994 depressogenic effect Effects 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 208000010643 digestive system disease Diseases 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 230000008451 emotion Effects 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- 238000002481 ethanol extraction Methods 0.000 description 1
- 239000000469 ethanolic extract Substances 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 230000035558 fertility Effects 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 206010016766 flatulence Diseases 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 230000005714 functional activity Effects 0.000 description 1
- 230000008717 functional decline Effects 0.000 description 1
- 230000030135 gastric motility Effects 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- 238000002657 hormone replacement therapy Methods 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229960003943 hypromellose Drugs 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 208000030208 low-grade fever Diseases 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000009245 menopause Effects 0.000 description 1
- 230000003821 menstrual periods Effects 0.000 description 1
- 210000000713 mesentery Anatomy 0.000 description 1
- 230000007102 metabolic function Effects 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 230000003020 moisturizing effect Effects 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- 229950007863 nilestriol Drugs 0.000 description 1
- 210000003101 oviduct Anatomy 0.000 description 1
- 230000027758 ovulation cycle Effects 0.000 description 1
- 230000036407 pain Effects 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 229960001412 pentobarbital Drugs 0.000 description 1
- 230000008855 peristalsis Effects 0.000 description 1
- 238000001050 pharmacotherapy Methods 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000001253 polyvinylpolypyrrolidone Substances 0.000 description 1
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 1
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000000186 progesterone Substances 0.000 description 1
- 229960003387 progesterone Drugs 0.000 description 1
- 239000000018 receptor agonist Substances 0.000 description 1
- 229940044601 receptor agonist Drugs 0.000 description 1
- 230000003014 reinforcing effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000001624 sedative effect Effects 0.000 description 1
- 239000009877 shengmai Substances 0.000 description 1
- 210000004894 snout Anatomy 0.000 description 1
- 235000015424 sodium Nutrition 0.000 description 1
- 239000007779 soft material Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000008925 spontaneous activity Effects 0.000 description 1
- 230000004206 stomach function Effects 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- 230000035922 thirst Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- 210000001215 vagina Anatomy 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 239000008539 xiaoyao Substances 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
Description
Claims (9)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2009102429773A CN101721637B (zh) | 2009-12-23 | 2009-12-23 | 一种治疗妇女更年期综合症的中药复方制剂及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2009102429773A CN101721637B (zh) | 2009-12-23 | 2009-12-23 | 一种治疗妇女更年期综合症的中药复方制剂及其制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN101721637A true CN101721637A (zh) | 2010-06-09 |
CN101721637B CN101721637B (zh) | 2011-12-21 |
Family
ID=42443587
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2009102429773A Active CN101721637B (zh) | 2009-12-23 | 2009-12-23 | 一种治疗妇女更年期综合症的中药复方制剂及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN101721637B (zh) |
Cited By (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102068597A (zh) * | 2010-11-19 | 2011-05-25 | 宋爱民 | 治疗更年期综合症的中药制剂 |
CN103405728A (zh) * | 2013-09-06 | 2013-11-27 | 梁怡芃 | 一种治疗更年期综合症的中药组合物及其制备方法 |
CN103495054A (zh) * | 2013-09-25 | 2014-01-08 | 牛艳红 | 一种治疗更年期综合症的中药制剂及制备方法 |
CN104689076A (zh) * | 2015-03-24 | 2015-06-10 | 臧兰恕 | 一种治疗热扰神明型失眠的中药组合物 |
CN104689205A (zh) * | 2015-04-02 | 2015-06-10 | 韩桂莲 | 一种治疗失眠多梦的中药制剂及制备方法 |
CN104689042A (zh) * | 2013-12-06 | 2015-06-10 | 陈筱韩 | 一种治疗女性更年期失眠的中药 |
CN104689081A (zh) * | 2015-04-02 | 2015-06-10 | 韩桂莲 | 治疗失眠的养心安神药剂 |
CN105288171A (zh) * | 2015-12-09 | 2016-02-03 | 青岛麦瑞特医药技术有限公司 | 一种治疗男性更年期综合征的药物组合物 |
CN111265614A (zh) * | 2020-02-21 | 2020-06-12 | 泉州永春达盛香业股份有限公司 | 一种解郁安神熏香及其制备方法 |
CN112245522A (zh) * | 2020-11-03 | 2021-01-22 | 平顶山学院 | 一种中药组合物及其在治疗女性围绝经期失眠药物中的应用 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101099838A (zh) * | 2007-07-12 | 2008-01-09 | 尹克华 | 治疗女性更年期综合症的中药 |
CN101129736A (zh) * | 2007-09-24 | 2008-02-27 | 北京艺信堂医药研究所 | 治疗更年期综合征的一种中药组合物 |
-
2009
- 2009-12-23 CN CN2009102429773A patent/CN101721637B/zh active Active
Cited By (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102068597A (zh) * | 2010-11-19 | 2011-05-25 | 宋爱民 | 治疗更年期综合症的中药制剂 |
CN103405728A (zh) * | 2013-09-06 | 2013-11-27 | 梁怡芃 | 一种治疗更年期综合症的中药组合物及其制备方法 |
CN103405728B (zh) * | 2013-09-06 | 2015-09-09 | 青岛市中心医院 | 一种治疗更年期综合症的中药组合物及其制备方法 |
CN103495054A (zh) * | 2013-09-25 | 2014-01-08 | 牛艳红 | 一种治疗更年期综合症的中药制剂及制备方法 |
CN103495054B (zh) * | 2013-09-25 | 2014-09-03 | 牛艳红 | 一种治疗更年期综合症的中药制剂及制备方法 |
CN104689042A (zh) * | 2013-12-06 | 2015-06-10 | 陈筱韩 | 一种治疗女性更年期失眠的中药 |
CN104689076A (zh) * | 2015-03-24 | 2015-06-10 | 臧兰恕 | 一种治疗热扰神明型失眠的中药组合物 |
CN104689205A (zh) * | 2015-04-02 | 2015-06-10 | 韩桂莲 | 一种治疗失眠多梦的中药制剂及制备方法 |
CN104689081A (zh) * | 2015-04-02 | 2015-06-10 | 韩桂莲 | 治疗失眠的养心安神药剂 |
CN105288171A (zh) * | 2015-12-09 | 2016-02-03 | 青岛麦瑞特医药技术有限公司 | 一种治疗男性更年期综合征的药物组合物 |
CN111265614A (zh) * | 2020-02-21 | 2020-06-12 | 泉州永春达盛香业股份有限公司 | 一种解郁安神熏香及其制备方法 |
CN112245522A (zh) * | 2020-11-03 | 2021-01-22 | 平顶山学院 | 一种中药组合物及其在治疗女性围绝经期失眠药物中的应用 |
Also Published As
Publication number | Publication date |
---|---|
CN101721637B (zh) | 2011-12-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101721637B (zh) | 一种治疗妇女更年期综合症的中药复方制剂及其制备方法 | |
CN102319389A (zh) | 一种治疗消化不良的药物 | |
CN101954037B (zh) | 一种治疗前列腺炎的中药制剂 | |
CN105663607A (zh) | 一种中药组合物及其制备方法和用途 | |
CN104922543A (zh) | 一种治疗闭经的药物组合物及其制备方法 | |
CN103041208A (zh) | 一种治疗妇女更年期综合征的中药制剂及其制备方法 | |
CN104225215A (zh) | 一种治疗失眠的中药 | |
CN102120020A (zh) | 一种治疗乳腺增生病和子宫肌瘤的药物组合物及其制备方法 | |
CN104383257A (zh) | 一种治疗肝郁阴虚型干眼症的中药制剂 | |
CN105456818A (zh) | 一种含有艾叶的治疗失眠的中药组合物及其制备方法 | |
CN115779064A (zh) | 一种黄芪扶正方及其制剂与应用 | |
CN102274417A (zh) | 治疗再生障碍性贫血的中成药 | |
CN102048913B (zh) | 一种治疗更年期综合症的中药制剂及其制备方法 | |
CN101450191B (zh) | 治疗不孕不育的药物及其制备方法 | |
CN100431595C (zh) | 用于气滞寒凝胃痛的药物组合物及其制备方法和用途 | |
CN103479783A (zh) | 一种治疗更年期抑郁症的中药组合物及其应用 | |
CN103007159A (zh) | 校正胰岛功能的中药制剂 | |
CN104800553A (zh) | 一种治疗更年期失眠症的中药组合物及其制备方法 | |
CN105362831A (zh) | 一种治疗失眠症的中药制剂 | |
CN105477302A (zh) | 一种治疗失眠症的中药组合物及其制备方法 | |
CN115624604B (zh) | 一种治疗更年期抑郁症的中药组合物及其制备方法与应用 | |
CN104547642A (zh) | 一种治疗女性纤维肌痛综合征的中药组合物 | |
CN109200162A (zh) | 一种治疗多囊卵巢综合征的中药制剂及制备方法 | |
CN102283993A (zh) | 一种治疗系统性红斑狼疮的中药组合物 | |
CN102038749B (zh) | 一种改善或预防围绝经期综合征的中药组合物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
ASS | Succession or assignment of patent right |
Owner name: BEIJING MANGE PHARMACEUTICAL TECHNOLOGY CORP. LTD. Effective date: 20120420 |
|
C41 | Transfer of patent application or patent right or utility model | ||
C53 | Correction of patent of invention or patent application | ||
CB03 | Change of inventor or designer information |
Inventor after: Fang Jian Inventor after: Wang Juan Inventor before: Fang Jian |
|
COR | Change of bibliographic data |
Free format text: CORRECT: INVENTOR; FROM: FANG JIAN TO: FANG JIAN WANG JUAN |
|
TR01 | Transfer of patent right |
Effective date of registration: 20120420 Address after: 100070 Beijing City, Fengtai District zaojiacheng Street South Lane No. 5 4A No. 2 layer Co-patentee after: BEIJING MANGE PHARMACEUTICAL S. & T. CO.,LTD. Patentee after: Dage International Medicine S&T (Beijing) Co.,Ltd. Address before: 100070 Beijing City, Fengtai District zaojiacheng Street South Lane No. 5 4A No. 2 layer Patentee before: Dage International Medicine S&T (Beijing) Co.,Ltd. |
|
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20200218 Address after: 135100 north one street, Tonghua Hui Nan County Economic Development Zone, Jilin Co-patentee after: BEIJING MANGE PHARMACEUTICAL S. & T. CO.,LTD. Patentee after: JILIN DESHANG PHARMACEUTICAL CO.,LTD. Address before: 100070 Beijing City, Fengtai District zaojiacheng Street South Lane No. 5 4A No. 2 layer Co-patentee before: BEIJING MANGE PHARMACEUTICAL S. & T. CO.,LTD. Patentee before: Dage International Medicine S&T (Beijing) Co.,Ltd. |
|
PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: The invention relates to a traditional Chinese medicine compound preparation for treating climacteric syndrome of women and a preparation method thereof Effective date of registration: 20210507 Granted publication date: 20111221 Pledgee: Tonghua Branch of China Everbright Bank Co.,Ltd. Pledgor: JILIN DESHANG PHARMACEUTICAL Co.,Ltd. Registration number: Y2021220000046 |
|
PC01 | Cancellation of the registration of the contract for pledge of patent right | ||
PC01 | Cancellation of the registration of the contract for pledge of patent right |
Date of cancellation: 20220810 Granted publication date: 20111221 Pledgee: Tonghua Branch of China Everbright Bank Co.,Ltd. Pledgor: JILIN DESHANG PHARMACEUTICAL CO.,LTD. Registration number: Y2021220000046 |
|
PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: A kind of traditional Chinese medicine compound preparation for treating women's menopausal syndrome and preparation method thereof Effective date of registration: 20220811 Granted publication date: 20111221 Pledgee: Tonghua Branch of China Everbright Bank Co.,Ltd. Pledgor: JILIN DESHANG PHARMACEUTICAL CO.,LTD. Registration number: Y2022220000054 |